| Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer |
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase 3 clinical trial. |
globenewswire.com |
2025-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript |
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Steve Kelsey - President-Research and Development Wei Lin - Chief Medical Officer Jack Anders - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Marc Frahm - TD Cowen Eric Joseph - J.P. Morgan Jonathan Chang - Leerink Partners Kelly Shi - Jefferies Ellie Merle - UBS Operator Good day, and thank you for standing by. |
seekingalpha.com |
2025-05-07 22:58:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress |
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2025, and provided an update on corporate progress. |
globenewswire.com |
2025-05-07 20:02:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 |
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. |
globenewswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting |
Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer |
globenewswire.com |
2025-04-27 16:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting |
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025. |
globenewswire.com |
2025-04-01 20:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Participate in April 2025 Investor Conferences |
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in in two upcoming investor conferences. |
globenewswire.com |
2025-03-31 20:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript |
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President-Research and Development Wei Lin - Chief Medical Officer Conference Call Participants Eric Joseph - J.P. Morgan Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Ben Burnett - Stifel Laura Prendergast - Raymond James Jay Olson - Oppenheimer Joe Catanzaro - Piper Sandler Poorna Kannan - Needham & Company Alex Bouilloux - Barclays Bank Operator Good day, and thank you for standing by. |
seekingalpha.com |
2025-02-27 11:05:53 |
Czytaj oryginał (ang.) |
| Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress |
Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026 Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025 Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif. |
globenewswire.com |
2025-02-26 18:02:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Participate in March 2025 Investor Conferences |
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. |
globenewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 |
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress. |
globenewswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-02-10 12:56:14 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference |
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET. |
globenewswire.com |
2025-01-29 18:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-01-16 12:35:28 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference |
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the 43r d Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT. |
globenewswire.com |
2025-01-06 18:05:00 |
Czytaj oryginał (ang.) |
| Insiders Are Loving These 6 Stocks Right Now |
The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly. |
247wallst.com |
2024-12-15 10:20:56 |
Czytaj oryginał (ang.) |
| Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares |
Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million |
globenewswire.com |
2024-12-05 18:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines: Risky Buy On Recent Share Price Dip |
Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDAC, with potential expansion into NSCLC and CRC, positioning it as a potential new standard of care. Despite a recent stock dip due to a $600m public offering, Revolution's robust cash position and promising pipeline offer significant long-term potential. |
seekingalpha.com |
2024-12-04 11:09:18 |
Czytaj oryginał (ang.) |
| Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants |
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offering price of $45.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are to be sold by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 2,445,652 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $750.0 million before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares and excluding the exercise of any pre-funded warrants. The offering is expected to close on December 5, 2024, subject to customary closing conditions. |
globenewswire.com |
2024-12-04 00:38:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines Announces Commencement of Public Offering of Common Stock |
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $600.0 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2024-12-02 18:31:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio |
Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial |
globenewswire.com |
2024-12-02 09:30:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 |
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio. |
globenewswire.com |
2024-11-27 18:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript |
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-06 21:52:10 |
Czytaj oryginał (ang.) |
| Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress |
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile |
globenewswire.com |
2024-11-06 18:02:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Participate in Upcoming Investor Conferences |
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker at Guggenheim's Inaugural Healthcare Innovation Conference and the UBS Global Healthcare Conference. |
globenewswire.com |
2024-11-05 11:00:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 |
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. |
globenewswire.com |
2024-10-30 18:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma |
First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC |
globenewswire.com |
2024-10-25 08:15:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma |
Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October 25 at 12:00 p.m. Eastern Time (ET) REDWOOD CITY, Calif. |
globenewswire.com |
2024-10-23 10:00:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma |
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, in patients with previously treated, metastatic pancreatic ductal adenocarcinoma (PDAC). |
globenewswire.com |
2024-10-21 20:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast |
Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations |
globenewswire.com |
2024-10-07 13:00:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript |
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President of R&D Wei Lin - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Chris Shibutani - Goldman Sachs Eliana Merle - UBS Alec Stranahan - Bank of America Kelly Shi - Jefferies Jay Olson - Oppenheimer Laura Prendergast - Raymond James Joseph Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to Revolution Medicine's Q2 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-11 06:00:27 |
Czytaj oryginał (ang.) |
| Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress |
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress. |
globenewswire.com |
2024-08-07 20:05:00 |
Czytaj oryginał (ang.) |
| Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024 |
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. |
globenewswire.com |
2024-07-31 20:05:00 |
Czytaj oryginał (ang.) |
| Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter |
As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. |
benzinga.com |
2024-07-16 12:16:01 |
Czytaj oryginał (ang.) |
| Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer |
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) |
globenewswire.com |
2024-07-11 16:00:00 |
Czytaj oryginał (ang.) |